Bayer AG
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- William N. Anderson
- Full Time Employees
- 88,078
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Kaiser-Wilhelm-Allee 1 Leverkusen NW Germany 51368
- IPO Date
- Nov 28, 1997
- Website
- bayer.com
- Similar Companies
- Business
- Bayer AG Bayer Aktiengesellschaft (BAYN.DE) is a German multinational life sciences company that develops, manufactures and markets products in pharmaceuticals; consumer health, including non-prescription medicines, nutritional supplements, skincare, digestive health and self-care solutions; and crop science, encompassing crop protection products such as fungicides, herbicides and insecticides, seeds, traits and digital farming technologies. Pharmaceuticals focuses on prescription medicines in cardiology, oncology, hematology, women's health, ophthalmology and radiology, featuring key brands including Nubeqa (darolutamide), Kerendia (finerenone), Xarelto (rivaroxaban), Eylea (aflibercept), Adempas (riociguat) and the Mirena intrauterine device family; consumer health offers over-the-counter products like Aspirin, Aleve, Berocca and Rennie for pain relief, allergy, cough and cold, dermatology and cardiovascular risk prevention; while crop science provides solutions like Liberty herbicide, Nativo fungicides and Poncho seed treatments for cereals, fruits, vegetables and non-crop pest control. The company operates globally across North America, Europe, Africa, Middle East, Asia-Pacific and Latin America, with approximately 96,000 employees and 2024 sales of €46.6 billion. Founded in 1863 in Barmen, Germany, by Friedrich Bayer, it is headquartered in Leverkusen, Germany. Recent developments include the September 2025 agreement to divest anti-infective Avelox globally, closing expected in Q1 2026; the August 2025 partnership with Kumquat Biosciences worth up to $1.3 billion for a KRAS G12D inhibitor oncology candidate targeting pancreatic, colorectal and lung cancers; submission of registration applications in October 2025 for novel herbicide icafolin-methyl in four major markets with launch planned from 2028 and peak sales potential of €750 million; extension of microbial nitrogen fixation collaboration with Ginkgo Bioworks; major expansion of satellite imagery access via Planet partnership in February 2025 for agricultural digital innovation; Q3 2025 sales of €9.7 billion with growth in Crop Science vegetable seeds and Pharmaceuticals brands like Nubeqa and Kerendia; and upcoming Board changes with Dr. Judith Hartmann appointed CFO effective June 2026, succeeding Wolfgang Nickl.
Company News
Bayer: Turnaround Is Gaining Momentum, But Debt Remains A Risk
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
Bayer to invest $2.2 billion in new US pharma site
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
Bayer faces trial test of remaining Roundup claims after US Supreme Court win
Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement
Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION